Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology

Fareed Khawaja; Genovefa Papanicolaou; Sanjeet Dadwal; Steven A. Pergam; John R. Wingard; Zeinab El Boghdadly; Maheen Z. Abidi; Alpana Waghmare; Zainab Shahid; Laura Michaels; Joshua A. Hill; Mini Kamboj; Michael Boeckh; Jeffery J. Auletta; Roy F. Chemaly

doi:10.1016/j.jtct.2022.10.010

Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology

Fareed Khawaja, Genovefa Papanicolaou, Sanjeet Dadwal, Steven A. Pergam, John R. Wingard, Zeinab El Boghdadly, Maheen Z. Abidi, Alpana Waghmare, Zainab Shahid, Laura Michaels, Joshua A. Hill, Mini Kamboj, Michael Boeckh, Jeffery J. Auletta, Roy F. Chemaly

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disproportionately affects immunocompromised and elderly patients. Not only are hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell recipients at greater risk for severe COVID-19 and COVID-19–related complications, but they also may experience suboptimal immune responses to currently available COVID-19 vaccines. Optimizing the use, timing, and number of doses of the COVID-19 vaccines in these patients may provide better protection against SARS-CoV-2 infection and better outcomes after infection. To this end, current guidelines for COVID-19 vaccination in HCT and CAR T-cell recipients from the American Society of Transplantation and Cellular Therapy Transplant Infectious Disease Special Interest Group and the American Society of Hematology are provided in a frequently asked questions format.

Original language	English (US)
Pages (from-to)	10-18
Number of pages	9
Journal	Transplantation and Cellular Therapy
Volume	29
Issue number	1
DOIs	https://doi.org/10.1016/j.jtct.2022.10.010
State	Published - Jan 2023

Keywords

Adenoviral vector vaccine
Bone marrow transplant
CAR T-cell
Chimeric antigen receptor T-cell
Coronavirus disease 2019
COVID-19
Hematopoietic cell transplant
mRNA vaccine
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccine safety

ASJC Scopus subject areas

Immunology and Allergy
Molecular Medicine
Hematology
Cell Biology
Transplantation

Access to Document

10.1016/j.jtct.2022.10.010

Fingerprint

Dive into the research topics of 'Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology'. Together they form a unique fingerprint.

Cite this

Khawaja, F., Papanicolaou, G., Dadwal, S., Pergam, S. A., Wingard, J. R., Boghdadly, Z. E., Abidi, M. Z., Waghmare, A., Shahid, Z., Michaels, L., Hill, J. A., Kamboj, M., Boeckh, M., Auletta, J. J., & Chemaly, R. F. (2023). Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. Transplantation and Cellular Therapy, 29(1), 10-18. https://doi.org/10.1016/j.jtct.2022.10.010

Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. / Khawaja, Fareed; Papanicolaou, Genovefa; Dadwal, Sanjeet et al.
In: Transplantation and Cellular Therapy, Vol. 29, No. 1, 01.2023, p. 10-18.

Research output: Contribution to journal › Article › peer-review

Khawaja, F, Papanicolaou, G, Dadwal, S, Pergam, SA, Wingard, JR, Boghdadly, ZE, Abidi, MZ, Waghmare, A, Shahid, Z, Michaels, L, Hill, JA, Kamboj, M, Boeckh, M, Auletta, JJ & Chemaly, RF 2023, 'Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology', Transplantation and Cellular Therapy, vol. 29, no. 1, pp. 10-18. https://doi.org/10.1016/j.jtct.2022.10.010

Khawaja F, Papanicolaou G, Dadwal S, Pergam SA, Wingard JR, Boghdadly ZE et al. Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. Transplantation and Cellular Therapy. 2023 Jan;29(1):10-18. doi: 10.1016/j.jtct.2022.10.010

Khawaja, Fareed ; Papanicolaou, Genovefa ; Dadwal, Sanjeet et al. / Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. In: Transplantation and Cellular Therapy. 2023 ; Vol. 29, No. 1. pp. 10-18.

@article{20878a7453834e53b5c74c9e10885219,

title = "Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology",

abstract = "Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disproportionately affects immunocompromised and elderly patients. Not only are hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell recipients at greater risk for severe COVID-19 and COVID-19–related complications, but they also may experience suboptimal immune responses to currently available COVID-19 vaccines. Optimizing the use, timing, and number of doses of the COVID-19 vaccines in these patients may provide better protection against SARS-CoV-2 infection and better outcomes after infection. To this end, current guidelines for COVID-19 vaccination in HCT and CAR T-cell recipients from the American Society of Transplantation and Cellular Therapy Transplant Infectious Disease Special Interest Group and the American Society of Hematology are provided in a frequently asked questions format.",

keywords = "Adenoviral vector vaccine, Bone marrow transplant, CAR T-cell, Chimeric antigen receptor T-cell, Coronavirus disease 2019, COVID-19, Hematopoietic cell transplant, mRNA vaccine, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, Vaccine safety",

author = "Fareed Khawaja and Genovefa Papanicolaou and Sanjeet Dadwal and Pergam, {Steven A.} and Wingard, {John R.} and Boghdadly, {Zeinab El} and Abidi, {Maheen Z.} and Alpana Waghmare and Zainab Shahid and Laura Michaels and Hill, {Joshua A.} and Mini Kamboj and Michael Boeckh and Auletta, {Jeffery J.} and Chemaly, {Roy F.}",

note = "Publisher Copyright: {\textcopyright} 2022 The American Society for Transplantation and Cellular Therapy",

year = "2023",

month = jan,

doi = "10.1016/j.jtct.2022.10.010",

language = "English (US)",

volume = "29",

pages = "10--18",

journal = "Transplantation and Cellular Therapy",

issn = "2666-6367",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology

AU - Khawaja, Fareed

AU - Papanicolaou, Genovefa

AU - Dadwal, Sanjeet

AU - Pergam, Steven A.

AU - Wingard, John R.

AU - Boghdadly, Zeinab El

AU - Abidi, Maheen Z.

AU - Waghmare, Alpana

AU - Shahid, Zainab

AU - Michaels, Laura

AU - Hill, Joshua A.

AU - Kamboj, Mini

AU - Boeckh, Michael

AU - Auletta, Jeffery J.

AU - Chemaly, Roy F.

PY - 2023/1

Y1 - 2023/1

N2 - Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disproportionately affects immunocompromised and elderly patients. Not only are hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell recipients at greater risk for severe COVID-19 and COVID-19–related complications, but they also may experience suboptimal immune responses to currently available COVID-19 vaccines. Optimizing the use, timing, and number of doses of the COVID-19 vaccines in these patients may provide better protection against SARS-CoV-2 infection and better outcomes after infection. To this end, current guidelines for COVID-19 vaccination in HCT and CAR T-cell recipients from the American Society of Transplantation and Cellular Therapy Transplant Infectious Disease Special Interest Group and the American Society of Hematology are provided in a frequently asked questions format.

AB - Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disproportionately affects immunocompromised and elderly patients. Not only are hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell recipients at greater risk for severe COVID-19 and COVID-19–related complications, but they also may experience suboptimal immune responses to currently available COVID-19 vaccines. Optimizing the use, timing, and number of doses of the COVID-19 vaccines in these patients may provide better protection against SARS-CoV-2 infection and better outcomes after infection. To this end, current guidelines for COVID-19 vaccination in HCT and CAR T-cell recipients from the American Society of Transplantation and Cellular Therapy Transplant Infectious Disease Special Interest Group and the American Society of Hematology are provided in a frequently asked questions format.

KW - Adenoviral vector vaccine

KW - Bone marrow transplant

KW - CAR T-cell

KW - Chimeric antigen receptor T-cell

KW - Coronavirus disease 2019

KW - COVID-19

KW - Hematopoietic cell transplant

KW - mRNA vaccine

KW - SARS-CoV-2

KW - Severe acute respiratory syndrome coronavirus 2

KW - Vaccine safety

UR - http://www.scopus.com/inward/record.url?scp=85144022739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85144022739&partnerID=8YFLogxK

U2 - 10.1016/j.jtct.2022.10.010

DO - 10.1016/j.jtct.2022.10.010

M3 - Article

C2 - 36273782

AN - SCOPUS:85144022739

SN - 2666-6367

VL - 29

SP - 10

EP - 18

JO - Transplantation and Cellular Therapy

JF - Transplantation and Cellular Therapy

IS - 1

ER -

Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this